Vericel Corp
VCEL
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
82.3% downsideOvervalued by 82.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.38 Billion |
|---|---|
| Enterprise Value | $2.37 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.33 |
| Beta | 1.07 |
| Outstanding Shares | 50,773,000 |
Return
| Return on Equity | 6.02% |
|---|---|
| Return on Assets | 4.42% |
| Return on Invested Capital | 4.02% |
Valuation & Multiples
| P/E Ratio | 108.72 |
|---|---|
| PEG | -247.3 |
| Price to Sales | 8.91 |
| Price to Book Ratio | 6.37 |
| Enterprise Value to Revenue | 8.1 |
| Enterprise Value to EBIT | 134.33 |
| Enterprise Value to Net Income | 110 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.27 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 198.76% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 6.68%▼ 102.89% |
|---|---|
| Total Invested | $150.84M▼ 91.54% |
| Investors Holding | 30▼ 254.00% |
ESG Score
No data
About Vericel Corp
CEO: Dominick Colangelo Relevant Senate Committees
The Finance Committee oversees Medicare and Medicaid; their decisions on reimbursement rates for advanced therapies are critical to Vericel's pricing strategy and commercial success.
This committee determines the exact funding levels for the FDA and the Department of Health and Human Services, directly impacting the speed of regulatory reviews and government procurement.
This committee directly regulates the FDA, which is the primary authority responsible for approving and overseeing Vericel's cell-based therapies and medical devices.